Back

GJA4 gene inhibition may represent a potential target for novel antithrombotic therapies

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Biomarkers to assess cardiovascular risk Cardiovascular Risk Assessment ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Debora Sa

Hospital Dr. Nelio Mendonca, Funchal (Portugal)

6 More presentations in this session

Presentation thumbnail
Expression of myostatin and folistatin as a response to high-load strength training to counteract the loss of muscle mass in heart failure with preserved ejection fraction
Doctor J. Lara Vargas (Ciudad de Mexico, MX)
Abstract Slides Video
Presentation thumbnail
Assessment of experimental circulating biomarkers in volume and pressure overload: insights from a cohort study
Mrs D. Csengeri (Hamburg, DE) Professor R. Schnabel (Hamburg, DE)
Abstract Slides Video
Presentation thumbnail
Circulating metabolites associate with the QT interval in individuals without prevalent cardiovascular disease.
Doctor W. Young (London, GB)
Abstract Slides Video
Presentation thumbnail
OSTEO18, a novel urinary proteomic signature, associated with osteoporosis in heart transplant recipients
Doctor Y. Yu (Leuven, BE)
Abstract Slides Video
Presentation thumbnail
AI-CAC significantly improves on Coronary Artery Calcium (CAC) score for predicting all cardiovascular events: the Multi-Ethnic Study of Atherosclerosis
Slides Video

Access the full session

Session thumbnail
Biomarkers to assess cardiovascular risk

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Is the HNF4A gene variant paradoxically associated with better prognostic in CAD patients?
thumbnail
Congress Presentation
Progress in understanding the genetic underpinning of coronary artery disease: from genotype to phenotype
thumbnail
Congress Presentation
Genetics could help the identification of coronary artery disease in smoker patients with few other cardiovascular risk factors

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources